Duration of untreated psychosis and social function: 1-Year follow-up study of first-episode schizophrenia

British Journal of Psychiatry

Volumn 193, Issue 3, 2008, Pages 203-209

  Barnes, Thomas R E ^a,e   Leeson, Verity C ^a   Mutsatsa, Stanley H ^a   Watt, Hilary C ^b   Hutton, Sam B ^c   Joyce, Eileen M ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; SCHIZOAFFECTIVE PSYCHOSIS; SOCIAL STATUS; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL ADJUSTMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 51449119640     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.049718     Document Type: Article

References (55)

1. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-7.
2. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-8.
3. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane JM. Gender differences in onset of illness, treatment response, course and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995; 152: 698-703.
4. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996; 2: 241-56.
5. Bottlender R, Strauss A, Möller HJ. Impact of duration of symptoms prior to first hospitalisation on acute outcome in 998 schizophrenic patients. Schizophr Res 2000; 44: 145-50.
6. Malla AK, Norman RMG, Manchanda R, Ahmed MR, Scholten D, Harricharan R, Cortese L, Takhar J. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res 2002; 54: 231-42.
7. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med 2003; 33: 97-110.
8. Addington J, van Mastrigt S, Addington D. Duration of untreated psychosis: impact on untreated 2-year outcome. Psychol Med 2004; 34: 277-84.
9. Wunderink A, Nienhuis FJ, Sytema S, Wiersma D. Treatment delay and response rate in first-episode psychosis. Acta Psychiatr Scand 2006; 113: 332-9.
10. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000; 157: 60-6.
11. Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 2000; 157: 808-15.
12. Verdoux H, Liraud F, Bergey C, Assens F, Abalan F, van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr Res 2001; 49: 231-41.
13. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-83.
14. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 2005; 162: 1785-804.
15. Rund BR, Melle I, Friis S, Larsen TK, Midbøe U, Opjordsmoen S, Simonsen E, Vaglum P, McGlashan T. Neurocognitive dysfunction in first episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 2004; 161: 466-72.
16. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 48: 239-46.
17. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, willson D, Israel L, Munich RL. The relative influences of symptoms, insight and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1999; 187: 102-8.
18. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
19. Barnes TRE, Hutton SB, Chapman MJ, Mutsatsa S, Puri BK, Joyce EM. West London first-episode study of schizophrenia: clinical correlates of duration of untreated psychosis. Br J Psychiatry 2000; 177: 207-11
20. Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TRE, Joyce EM. Executive function in first-episode schizophrenia. Psychol Med 1998; 28: 463-73.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
22. Andreasen N. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24: 73-88.
23. Liddle PF, Barnes TR. Syndromes of chronic schizophrenia. Br J Psychiatry 1990; 157: 558-61.
24. Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res 1996; 21: 1-12.
25. Liddle PF. The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry 1987; 151: 145-51.
26. Möller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TRE, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW, Gerlach J, Grafford K, Heutschel B, Hertkorn A, Heylen S, Lecrubier Y, Leonard JP, McKenna P, Maier W, Pedersen v, Rappard A, Rein W, Ryan J, Nielsen MS, Stieglitz R-D, Wegener G, Wilson J. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 1994; 115: 221-8.
27. Nelson HE. National Adult Reading Test (NART), second Version: Test Manual. nferNelson, 1991.
28. Wechsler D. The Wechsler Adult Intelligence Scale - Revised Manual. Psychological Corporation, 1981.
29. Sahakian BJ, Owen AM. Computerised assessment in neuropsychiatry using CANTAB: discussion paper. J Roy Soc Med 1992; 85: 399-402.
30. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990; 157: 853-9.
31. Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G, for the HGDH Research Group. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185: 18-24.
32. Barnes TRE, Liddle PF. Evidence for the validity of negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24: 43-72.
33. Üçok A, Polat A, Genç A, Cakir S, Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 2004; 38: 163-8.
34. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 2000; 177: 511-5.
35. Kalla O, Aaltonen J, Wahlstrom J, Lehtinen V, Garcia Cabeza I, Gonzalez de Chavez M. Duration of untreated psychosis and its correlates in first episode psychosis in Finland and Spain. Acta Psychiatr scand 2002; 106: 265-75.
36. McGorry PD, Edwards J, Mihalopplous C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996; 22: 305-26.
37. Oosthuizen P, Emsley RA, Keyter N, Niehaus DJH, Koen L. Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country. Acta Psychiatr Scand 2005; 111: 214-9.
38. Malla AK, Norman RMG, Takhar J, Townsend L, Scholten D, Haricharan R. Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis? J Nerv Ment Dis 2004; 192: 455-63.
39. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000; 45: 1-9.
40. Schmitz N, Malla A, Norman R, Archie S, Zipursky R. Inconsistency in the relationship between duration of untreated psychosis (DUP) and negative symptoms: sorting out the problem of heterogeneity. Schizophr Res 2007; 93: 152-9.
41. Edwards J, Harrigan SM, McGorry PD, Amminger GP. Duration of untreated psychosis (DUP) and outcome in schizophrenia. Psychol Med 2002; 32: 563-4.
42. Norman RMG, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry 2005; 187 (suppl 48): S519-23.
43. Peralta v, Cuesta MJ. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr Res 1999; 38: 13-26.
44. Joyce E, Hutton S, Mutsatsa S, Gibbins H, Webb E, Paul S, Robbins T, Barnes TRE. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry 2002; 181 (suppl 43): S38-44.
45. Hoff AL, Sakuma M, Heydebrand G, Heydebrand G, Csernansky JG, DeLisi LE. Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am J Psychiatry 2000; 157: 1824-8.
46. Norman RMG, Townsend L, Malla AK. Duration of untreated psychosis and cognitive functioning in first-episode patients. Br J Psychiatry 2001; 179: 340-5.
47. Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS, Arndt S, Andreasen NC. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry 2003; 160: 142-8.
48. Joyce EM, Hutton SB, Mutsatsa SH, Barnes TRE. Cognitive heterogeneity in first-episode schizophrenia. Br J Psychiatry 2005; 187: 516-22.
49. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51.
50. Keshavan MS, Haas GL, Kahn CE, Aguilar E, Dick EL, Schooler NR, Sweeney JA, Pettegrew JW. Superior temporal gyrus and the course of early schizophrenia: progressive, static or reversible? J Psychiatry Res 1998; 32: 161-7.
51. Lappin JM, Morgan K, Morgan C, Hutchison G, Chitnis X, Suckling J, Fearon P, McGuire PK, Jones PB, Leff J, Murray RM, Dazzan P. Gray matter abnormalities associated with duration of untreated psychosis. Schizophr Res 2006; 83: 145-53.
52. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural changes subsequent to the onset of schizophrenia. Psychiatr Res 1997; 74: 129-40.
53. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tonen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first episode psychosis: a randomised double blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985-95.
54. Addington J, Saeedi H, Addington D. Influence of social perception and social knowledge on cognitive and social functioning in early psychosis. Br J Psychiatry 2006; 189: 373-8.
55. Brekke JS, Hoe M, Long J, Green MF. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull 2007; 33: 1247-56.